异动解读｜和黄医药盘中上涨5.3%，与葛兰素史克达成最高12.95亿美元授权合作提振延续

行情直击09-04

9月4日，和黄医药盘中上涨5.3%，报23.26港元，成交额1.14亿港元，延续前一交易日强势表现。

消息面上，公司9月3日宣布旗下和记黄埔医药与葛兰素史克附属公司达成独家开发及许可协议，授予后者在中国大陆、港澳台以外的全球范围内开发和商业化全球首创KRAS-EGFR抗体靶向偶联药物HMPL-A830的权利，首批适应症聚焦结直肠癌、胰腺癌和肺癌。协议包含1.1亿美元首付款，叠加开发、注册及商业化里程碑付款，总额最高可达12.95亿美元，另含基于净销售额的特许权使用费。该消息于前一交易日已推动股价大涨逾16%，今日涨势为市场对这一重磅授权合作的情绪延续。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1107128857?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-04 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107128857","market":"hk","top_or_hot":-1,"title":"异动解读｜和黄医药盘中上涨5.3%，与葛兰素史克达成最高12.95亿美元授权合作提振延续","media":"行情直击","content":"<p><p>9月4日，和黄医药盘中上涨5.3%，报23.26港元，成交额1.14亿港元，延续前一交易日强势表现。</p><p>消息面上，公司9月3日宣布旗下和记黄埔医药与葛兰素史克附属公司达成独家开发及许可协议，授予后者在中国大陆、港澳台以外的全球范围内开发和商业化全球首创KRAS-EGFR抗体靶向偶联药物HMPL-A830的权利，首批适应症聚焦结直肠癌、胰腺癌和肺癌。协议包含1.1亿美元首付款，叠加开发、注册及商业化里程碑付款，总额最高可达12.95亿美元，另含基于净销售额的特许权使用费。该消息于前一交易日已推动股价大涨逾16%，今日涨势为市场对这一重磅授权合作的情绪延续。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜和黄医药盘中上涨5.3%，与葛兰素史克达成最高12.95亿美元授权合作提振延续</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜和黄医药盘中上涨5.3%，与葛兰素史克达成最高12.95亿美元授权合作提振延续\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-04 09:35 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月4日，和黄医药盘中上涨5.3%，报23.26港元，成交额1.14亿港元，延续前一交易日强势表现。消息面上，公司9月3日宣布旗下和记黄埔医药与葛兰素史克附属公司达成独家开发及许可协议，授予后者在中国大陆、港澳台以外的全球范围内开发和商业化全球首创KRAS-EGFR抗体靶向偶联药物HMPL-A830的权利，首批适应症聚焦结直肠癌、胰腺癌和肺癌。协议包含1.1亿美元首付款，叠加开发、注册及商业化...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00013","symbol_name":"和黄医药","start_time":0,"source_url":"","article_id":"1107128857","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107128857","pubTimestamp":1788485702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"9月4日，和黄医药盘中上涨5.3%，报23.26港元，成交额1.14亿港元，延续前一交易日强势表现。协议包含1.1亿美元首付款，叠加开发、注册及商业化里程碑付款，总额最高可达12.95亿美元，另含基于净销售额的特许权使用费。该消息于前一交易日已推动股价大涨逾16%，今日涨势为市场对这一重磅授权合作的情绪延续。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00013":"和黄医药"},"translate_title":"Unusual Movement Analysis | Hutchison MediPharma rose 5.3% intraday, boosted by a licensing partnership with GlaxoSmithKline of up to $1.295 billion.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1},"content_text":"9月4日，和黄医药盘中上涨5.3%，报23.26港元，成交额1.14亿港元，延续前一交易日强势表现。消息面上，公司9月3日宣布旗下和记黄埔医药与葛兰素史克附属公司达成独家开发及许可协议，授予后者在中国大陆、港澳台以外的全球范围内开发和商业化全球首创KRAS-EGFR抗体靶向偶联药物HMPL-A830的权利，首批适应症聚焦结直肠癌、胰腺癌和肺癌。协议包含1.1亿美元首付款，叠加开发、注册及商业化里程碑付款，总额最高可达12.95亿美元，另含基于净销售额的特许权使用费。该消息于前一交易日已推动股价大涨逾16%，今日涨势为市场对这一重磅授权合作的情绪延续。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107128857","isCrawlerRequest":true}